Skip to main content
. 2023 Apr 28;15(5):1361. doi: 10.3390/pharmaceutics15051361

Table 2.

Methodological quality of the included studies according to the Risk of Bias 2.0 tool.

Included Study D1 D2 D3 D4 D5 Overall
Jin 2004 [59] Sc H H L Sc H
Sun 2008 [60] Sc H H Sc Sc H
Shen 2009 [61] L H H L Sc H
Lin 2010 [62] Sc H H L Sc H
Wang 2010 [63] L H H L Sc H
Yan 2010 [64] Sc H H Sc Sc H
Wu 2011 [65] Sc H H L Sc H
Gao 2012 [66] Sc H H L Sc H
Gong 2013 [67] Sc H H L Sc H
Han 2013 [68] L H H Sc Sc H
Zhang 2013a [69] L H H L Sc H
Zhang 2013b [70] Sc H H L Sc H
Guo 2014 [71] Sc H H Sc Sc H
Yang 2014a [73] Sc H H Sc Sc H
Yang 2014b [72] L H H Sc Sc H
Qi 2015 [74] Sc H H L Sc H
Wang 2015 [75] Sc H H Sc Sc H
Xue 2015 [76] L H H L Sc H
Guo 2016 [77] L H H L Sc H
Han 2016 [78] Sc H H L Sc H
Lan 2016 [79] H H H L Sc H
Mo 2016 [82] L H H Sc Sc H
Wang 2016 [83] L H H Sc Sc H
Li 2016a [80] L H H L Sc H
Zhang 2016a [85] L H H L Sc H
Li 2016b [81] Sc H H L Sc H
Zhang 2016b [84] L H H L Sc H
Chen 2017 [86] L H H L Sc H
Shi 2017 [87] Sc H H L Sc H
Wang 2017 [88] L H H L Sc H
Chen 2018 [89] L H H Sc Sc H
Dai 2018 [90] H H H L Sc H
Hu 2018 [92] Sc H H L Sc H
Huang 2018 [93] L H H L Sc H
She 2018 [94] L H H L Sc H
Xin 2018 [95] H H H Sc Sc H
Gao 2019 [91] Sc H H L Sc H
Wu 2019 [99] L H H L Sc H
Yi 2019 [100] L H H L Sc H
Ji 2019 [96] L H H Sc Sc H
Liu 2019a [97] Sc H H L Sc H
Liu 2019b [98] Sc H H Sc Sc H
Chen 2021 [101] Sc H Sc L Sc H
Hou 2021 [102] Sc H H L Sc H
Li 2021 [103] L H H L Sc H
Wang 2021a [105] L H H L Sc H
Wang 2021b [104] L H H L Sc H
Zhang 2021 [106] H H H L Sc H

D1–D5: five domain criteria; D1: bias arising from the randomization process; D2: bias due to deviations from intended interventions; D3: bias due to missing outcome data; D4: bias in the measurement of the outcome; D5: bias in the selection of the reported results; H: high risk of bias; L: low risk of bias; Sc: some concerns.